We do not accept Medi-cal and blue shield insurances.

Ozempic Mounjaro Benefits Beyond Weight Loss

Here are some of the amazing benefits of GLP-1 receptor agonists:

1. **Weight Reduction in Obesity**:

- **Semaglutide**: In a study published in the *New England Journal of Medicine*, patients treated with semaglutide 2.4 mg weekly experienced an average weight loss of 14.9% over 68 weeks compared to 2.4% in the placebo group .

- **Liraglutide**: A clinical trial demonstrated that patients using liraglutide 3.0 mg daily lost an average of 8.4% of their body weight, compared to 2.8% in the placebo group over 56 weeks .

 

2. **Appetite Suppression**:

- **Mechanisms**: GLP-1 receptor agonists act on the hypothalamus to decrease appetite. They slow gastric emptying, leading to prolonged feelings of fullness .

- **Effectiveness**: Studies have shown that individuals on GLP-1 agonists report a 15-25% reduction in daily caloric intake .

### Diabetes Management

1. **Improved Glycemic Control**:

- **HbA1c Reduction**: A meta-analysis reported that GLP-1 receptor agonists reduce HbA1c by approximately 1.0-1.5% compared to baseline values in patients with type 2 diabetes .

- **Fasting Blood Glucose**: These medications can lower fasting blood glucose levels by 20-40 mg/dL (1.1-2.2 mmol/L) .

2. **Cardiovascular Benefits**:

- **LEADER Trial (Liraglutide)**: The LEADER trial found a 13% reduction in major adverse cardiovascular events (MACE) with liraglutide compared to placebo (HR, 0.87; 95% CI, 0.78-0.97; p=0.01) .

- **SUSTAIN-6 Trial (Semaglutide)**: The SUSTAIN-6 trial demonstrated a 26% reduction in MACE with semaglutide (HR, 0.74; 95% CI, 0.58-0.95; p=0.02) .

### Treating Addiction

1. **Alcohol Addiction**:

- **Animal Studies**: Preclinical studies have shown a reduction in alcohol intake by 20-40% in rodents treated with GLP-1 receptor agonists .

- **Early Clinical Trials**: Small-scale human studies indicate a decrease in alcohol craving and consumption, though larger trials are needed for confirmation .

2. **Nicotine and Drug Addiction**:

- **Nicotine**: Preliminary research suggests GLP-1 receptor agonists might reduce nicotine addiction by modulating the brain's reward pathways .

- **Opioids and Cocaine**: Early studies in animal models show potential in reducing drug-seeking behavior, but human data is still limited .

### Other Potential Benefits

1. **Neuroprotection**:

- **Alzheimer's Disease**: Research has shown that GLP-1 receptor agonists can reduce amyloid plaques and tau tangles by up to 50% in animal models, suggesting potential therapeutic effects .

- **Parkinson's Disease**: Studies indicate improvements in motor function and reductions in neuroinflammation in animal models .

2. **Non-Alcoholic Fatty Liver Disease (NAFLD)**:

- **Liver Fat Reduction**: A phase 2 trial reported that liraglutide led to a 31% reduction in liver fat content in patients with NASH .

- **Liver Inflammation**: Significant improvements in liver inflammation and fibrosis were observed, with some patients showing complete resolution of NASH .

3. **Improved Renal Outcomes**:

- **Diabetic Nephropathy**: The LEADER trial also found that liraglutide reduced the progression of diabetic nephropathy by 22% (HR, 0.78; 95% CI, 0.67-0.92; p=0.003) .

- **Overall Renal Protection**: GLP-1 receptor agonists are linked to a reduction in albuminuria and a slower decline in estimated glomerular filtration rate (eGFR) . These detailed insights highlight the extensive benefits of GLP-1 receptor agonists across various health conditions.

 

### References 1. Wadden, T. A., et al. (2021). "Weight loss and health outcomes with semaglutide in patients with obesity." *New England Journal of Medicine*. 2. Rubino, D., et al. (2021). "Effect of weekly subcutaneous semaglutide on weight loss in adults with overweight or obesity." *JAMA*. 3. Lund, A., et al. (2017). "Mechanisms of GLP-1-induced weight loss in humans." *Obesity Reviews*. 4. Marso, S. P., et al. (2016). "Liraglutide and cardiovascular outcomes in type 2 diabetes." *New England Journal of Medicine*. 5. Marso, S. P., et al. (2016). "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." *New England Journal of Medicine*. 6. Gerstein, H. C., et al. (2019). "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)." *Lancet*. 7. Shirazi, R. H., et al. (2013). "The glucagon-like peptide-1 (GLP-1) receptor as a therapeutic target for neuropsychiatric and neurodegenerative disorders." *Journal of Pharmacology and Experimental Therapeutics*. 8. Vallöf, D., et al. (2016). "GLP-1 receptors regulate alcohol-mediated behaviors in the nucleus accumbens." *Alcoholism: Clinical and Experimental Research*. 9. Schmidt, H. D., et al. (2016). "Glucagon-like peptide-1 receptor agonists for the treatment of addiction." *Brain Research*. 10. Hölscher, C. (2014). "Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases." *Journal of Endocrinology*. 11. Armstrong, M. J., et al. (2016). "Liraglutide and non-alcoholic steatohepatitis: a phase 2 randomized, placebo-controlled trial." *Lancet*. 12. Mann, J. F. E., et al. (2017). "Liraglutide and renal outcomes in type 2 diabetes." *New England Journal of Medicine*.

Author
Afshine Ash Emrani, MD, FACC Internal Medicine, Cardiology

You Might Also Enjoy...

Leqvio

A promising new drug that can help reduce LDL: Leqvio

Leqvio is a new type of medication called a small interfering RNA (siRNA) therapy. It works by targeting a specific protein in the liver called PCSK9, which is responsible for removing LDL (low-density lipoprotein) cholesterol from the blood.
Dr. Emrani's Medically Supervised Weight Loss Program

Medical Weight Loss Program with Ozempic/ Wegovy/ Mounjaro

I am pleased to announce that we are now accepting new patients into our medically supervised weight loss program. My goal is to not only help individuals lose weight but to develop sustainable lifestyle changes through the use of medications.